云南高校图书馆联盟文献共享服务平台- LAPATINIB

LAPATINIB: 作品数：36被引量：110H指数：6; 导出分析报告; 相关领域：医药卫生更多>>; 相关作者：符立梧戴春岭汪延生李青王海琳更多>>; 相关机构：中山大学天津医科大学新乡医学院中国医科大学更多>>; 相关期刊：《临床和实验医学杂志》《中国药理学通报》《中国肿瘤》《中国现代药物应用》更多>>; 相关基金：国家自然科学基金北京市卫生系统高层次卫生技术人才培养项目北京市自然科学基金云南省科技厅科研基金更多>>

HER-2阳性乳腺癌伴肺转移患者临床治疗中Lapatinib靶向治疗联合顺铂、卡培他滨化疗治疗效果分析: 《中文科技期刊数据库（引文版）医药卫生》2024年第11期092-095,共4页冯丽丽; 分析Lapatinib(拉帕替尼)靶向治疗联合顺铂、卡培他滨化疗治疗HER-2阳性乳腺癌伴肺转移患者的效果。方法将80例患者作为研究对象,患者入院时间为2022年6月到2023年12月,患者均患有乳腺癌伴肺转移疾病。根据随机数表法分组,分为对照组(n...; 关键词：HER-2阳性乳腺癌肺转移 LAPATINIB 顺铂卡培他滨效果

Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer: 《World Journal of Clinical Oncology》2023年第5期198-202,共5页Aya Abunada Zaid Sirhan Anita Thyagarajan Ravi P Sahu; Supported by the Elsa U.Pardee Foundation Grant,No.671432(to Sahu RP);NIH R21 Grant,No.ES033806(to Sahu RP).; The body of evidence investigating human epidermal growth factor receptor-2(HER2)directed therapy in patients with breast cancer(BC)has been growing within the last decade.Recently,the use of tyrosine kinase inhibitor...; 关键词：Human epidermal growth factor receptor-2 positive breast cancer Tyrosine kinase inhibitors LAPATINIB Pyrotinib Tucatinib TRASTUZUMAB

Lapatinib靶向治疗联合顺铂+卡培他滨化疗方案治疗HER-2阳性乳腺癌伴肺转移的价值分析被引量：1: 《中国现代药物应用》2022年第4期13-16,共4页刘畅; 目的观察人表皮生长因子受体2(HER-2)阳性乳腺癌伴肺转移患者应用拉帕替尼(Lapatinib)靶向治疗联合顺铂+卡培他滨化疗方案的效果。方法118例HER-2阳性乳腺癌伴肺转移患者,采用随机数字表法分为观察组和对照组,各59例。对照组给予顺铂+...; 关键词：人表皮生长因子受体2阳性乳腺癌肺转移卡培他滨拉帕替尼化疗方案

Dehydroheliobuphthalmin与Lapatinib联合应用靶向抑制NCI-H441细胞的研究被引量：1: 《西南农业学报》2021年第7期1425-1432,共8页罗锐赵月爨向丹杨星莹朱威巍黄艳苹王宣军盛军; 云南省科技厅基金项目(2018IA060、017ZF003、2018ZG010、2018ZG013)。; 【目的】在细胞水平上探讨Dehydroheliobuphthalmin(Dehy)与Lapatinib(Lap)联合应用(Dehy+Lap)的潜在抗肿瘤机制。【方法】利用MTT,Western Blotting等方法以EGFR(wild-type)细胞NCI-H441和EGFR(mutant)细胞NCI-H1975为研究对象,对比不...; 关键词：Dehydroheliobuphthalmin LAPATINIB NCI-H441

Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report: 《World Journal of Gastrointestinal Oncology》2020年第9期1065-1072,共8页Ji-Lin Guan Jian-Hua Liu Qing Wang Yu-Wei Cong Yao-Xu Chen Ke-Fei Huang Meng-Li Huang Ling Huang; BACKGROUND Human epidermal growth factor receptor 2(HER2)amplification is a molecular driver for a subset of colorectal cancers(CRCs)and one of the major causes of anti-epidermal growth factor receptor(EGFR)treatment ...; 关键词：Human epidermal growth factor receptor 2 Colorectal cancer LAPATINIB Circulating tumor DNA Case report

Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer:opportunities to overcome a difficult problem被引量：3: 《Cancer Drug Resistance》2020年第2期179-198,共20页Reema Wahdan-Alaswad Bolin Liu Ann D.Thor; Grant support provided in part by Susan G Komen for the Cure K100575 to RSW,SME,and ADT;ACS-IRG 16-184-56 RSW from the American Cancer Society;CCL-C92110 RSW and ADT from the Colorado Cancer League.; Approximately 20%of invasive breast cancers have upregulation/gene amplification of the oncogene human epidermal growth factor receptor-2(HER2/ErbB2).Of these,some also express steroid receptors(the so-called Luminal ...; 关键词：HER2/ErbB2 receptor tyrosine kinase tyrosine kinase resistance nuclear receptor androgen receptor lipid metabolism programmed cell death-1 ligand CDK 4/6 inhibitor

Bexarotene combined with lapatinib for the treatment of Cushing’s disease:evidence based on drug repositioning and experimental confirmation被引量：1: 《Signal Transduction and Targeted Therapy》2020年第1期988-990,共3页Haoying Yu Shuyue Ren Jingrong Wang Tingting Lv Lan Sun Guanhua Du; supported by National Natural Science Foundation of China(Grant No:81670456);Drug Innovation Major Project of China(No.2018ZX09711001-003-001);Natural Science Foundation of Beijing Municipality(CN)(Grant No:7162132);CAMS Innovation Fund for Medical Sciences(Grant No:2017-I2M-1-011).; Dear Editor,Cushing’s disease(CD)is a rare disease manifested as Cushing’s syndrome caused by adrenocorticotropic hormone(ACTH)consistently over-secreted by adrenocorticotropic adenomas,followed by stimulation of th...; 关键词：CUSHING DRUGS TREATMENT

Lapatinib靶向治疗乳腺癌HER_2阳性伴肺转移患者对肿瘤标志物表达的影响作用分析被引量：4: 《中国医药指南》2019年第4期139-140,共2页王勇; 目的观察乳腺癌HER_2阳性合并肺转移者接受Lapatinib靶向治疗,对肿瘤标志物表达效果产生的影响。方法选择笔者科室于2016年4月2017年8月期间收治的65例乳腺癌HER2阳性合并肺转移患者,随机分为A组30例(顺铂+卡培他滨化疗)与B组35例(A组...; 关键词：乳腺癌 HER2 肺转移 LAPATINIB 肿瘤标志物疗效观察影响分析

Trastuzumab,not lapatinib,has therapeutic effects on Chinese patients with HER2-positive cholangiocarcinoma: 《Hepatobiliary & Pancreatic Diseases International》2018年第5期477-479,共3页Hai-Bo Mou Wen-Dong Li Yan-Jun Shen Jun-Ping Shi Xiao-Di Guo Ming Yao Kai Wang Ting Zhang; supported by a grant from Department of Education of Zhejiang Province(Y201636437); As a relatively uncommon orphan tumor with high mortality,biliary tract cancer(BTC)presents an aggressive course and heterogeneous clinical features[1].BTC patients present with advanced manifestations[2].Unfortunatel...; 关键词：BILIARY TRACT cancer(BTC) next generation sequencing(NGS)

Lapatinib靶向治疗乳腺癌HER2阳性伴肺转移患者对肿瘤标志物表达的影响作用被引量：4: 《标记免疫分析与临床》2018年第7期1021-1024,共4页周勇李靖彭世军; 目的探究Lapatinib靶向治疗乳腺癌HER2阳性伴肺转移患者对肿瘤标志物表达的影响作用。方法选取2013年1月至2015年1月期间在恩施土家族苗族自治州中心医院确诊为乳腺癌HER2阳性且伴有肺转移的108例女性患者,根据数字表法随机分为观察组...; 关键词：LAPATINIB 乳腺癌 HER2 肿瘤标志物

LAPATINIB